These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37169177)

  • 1. Mannose 6-phosphate receptor-targeting antibodies preserve Fc receptor-mediated recycling.
    Gauthier C; Mariot J; Daurat M; Dhommée C; El Cheikh K; Morère E; Depaepe G; Gary-Bobo M; Morère A; Garcia M; Basile I; Gouilleux-Gruart V; Maynadier M
    J Control Release; 2023 Jun; 358():465-475. PubMed ID: 37169177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineered therapeutic antibodies with mannose 6-phosphate analogues as a tool to degrade extracellular proteins.
    Daurat M; Gauthier C; El Cheikh K; Ali LMA; Morère E; Bettache N; Gary-Bobo M; Morère A; Garcia M; Maynadier M; Basile I
    Front Immunol; 2024; 15():1273280. PubMed ID: 38533506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
    Gurbaxani B; Dostalek M; Gardner I
    Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer.
    Porter C; Armstrong-Fisher S; Kopotsha T; Smith B; Baker T; Kevorkian L; Nesbitt A
    J Reprod Immunol; 2016 Aug; 116():7-12. PubMed ID: 27123565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient therapy for refractory Pompe disease by mannose 6-phosphate analogue grafting on acid α-glucosidase.
    Basile I; Da Silva A; El Cheikh K; Godefroy A; Daurat M; Harmois A; Perez M; Caillaud C; Charbonné HV; Pau B; Gary-Bobo M; Morère A; Garcia M; Maynadier M
    J Control Release; 2018 Jan; 269():15-23. PubMed ID: 29108866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct demonstration of a neonatal Fc receptor (FcRn)-driven endosomal sorting pathway for cellular recycling of albumin.
    Schmidt EGW; Hvam ML; Antunes F; Cameron J; Viuff D; Andersen B; Kristensen NN; Howard KA
    J Biol Chem; 2017 Aug; 292(32):13312-13322. PubMed ID: 28637874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.
    Monnet C; Jorieux S; Souyris N; Zaki O; Jacquet A; Fournier N; Crozet F; de Romeuf C; Bouayadi K; Urbain R; Behrens CK; Mondon P; Fontayne A
    MAbs; 2014; 6(2):422-36. PubMed ID: 24492301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic antibody engineering for efficient targeted degradation of membrane proteins in lysosomes.
    Gauthier C; Daurat M; Ali LMA; El Cheikh K; El Bahlagui I; Taliercio C; Morère E; Gary-Bobo M; Morère A; Garcia M; Maynadier M; Basile I
    Biomed Pharmacother; 2024 Jun; 175():116707. PubMed ID: 38739989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys.
    Deng R; Loyet KM; Lien S; Iyer S; DeForge LE; Theil FP; Lowman HB; Fielder PJ; Prabhu S
    Drug Metab Dispos; 2010 Apr; 38(4):600-5. PubMed ID: 20071453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.
    Piche-Nicholas NM; Avery LB; King AC; Kavosi M; Wang M; O'Hara DM; Tchistiakova L; Katragadda M
    MAbs; 2018 Jan; 10(1):81-94. PubMed ID: 28991504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Minimal Physiologically Based Pharmacokinetic Model with a Nested Endosome Compartment for Novel Engineered Antibodies.
    Yuan D; Rode F; Cao Y
    AAPS J; 2018 Mar; 20(3):48. PubMed ID: 29541870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies.
    Stracke J; Emrich T; Rueger P; Schlothauer T; Kling L; Knaupp A; Hertenberger H; Wolfert A; Spick C; Lau W; Drabner G; Reiff U; Koll H; Papadimitriou A
    MAbs; 2014; 6(5):1229-42. PubMed ID: 25517308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FcRn-Dependent Transcytosis of Monoclonal Antibody in Human Nasal Epithelial Cells In Vitro: A Prerequisite for a New Delivery Route for Therapy?
    Bequignon E; Dhommée C; Angely C; Thomas L; Bottier M; Escudier E; Isabey D; Coste A; Louis B; Papon JF; Gouilleux-Gruart V
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30893823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toward in vitro-to-in vivo translation of monoclonal antibody pharmacokinetics: Application of a neonatal Fc receptor-mediated transcytosis assay to understand the interplaying clearance mechanisms.
    Jaramillo CAC; Belli S; Cascais AC; Dudal S; Edelmann MR; Haak M; Brun ME; Otteneder MB; Ullah M; Funk C; Schuler F; Simon S
    MAbs; 2017 Jul; 9(5):781-791. PubMed ID: 28440708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey.
    Ng CM; Loyet KM; Iyer S; Fielder PJ; Deng R
    Eur J Pharm Sci; 2014 Jan; 51():51-8. PubMed ID: 23999033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Physiologically-Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data.
    Jones HM; Zhang Z; Jasper P; Luo H; Avery LB; King LE; Neubert H; Barton HA; Betts AM; Webster R
    CPT Pharmacometrics Syst Pharmacol; 2019 Oct; 8(10):738-747. PubMed ID: 31464379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering neonatal Fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions.
    Sockolosky JT; Tiffany MR; Szoka FC
    Proc Natl Acad Sci U S A; 2012 Oct; 109(40):16095-100. PubMed ID: 22991460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Localization of the human neonatal Fc receptor (FcRn) in human nasal epithelium.
    Heidl S; Ellinger I; Niederberger V; Waltl EE; Fuchs R
    Protoplasma; 2016 Nov; 253(6):1557-1564. PubMed ID: 26634928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies.
    Datta-Mannan A; Lu J; Witcher DR; Leung D; Tang Y; Wroblewski VJ
    MAbs; 2015; 7(6):1084-93. PubMed ID: 26337808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors.
    Goulet DR; Zwolak A; Williams JA; Chiu ML; Atkins WM
    Proteins; 2020 May; 88(5):689-697. PubMed ID: 31702857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.